Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release


Posted on: 31 Oct 16

- Data show that hospitals may require significantly less resource use if rifaximin-α is used1

LONDON, UK, Monday 31 October 2016, 15:00 GMT. Norgine B.V. today presented new UK real world data, IMPRESS, that show rifaximin-α for the treatment of hepatic encephalopathy could reduce costs related to non-elective hospital admissions, critical care bed occupancy, emergency room visits and 30-day emergency re-admissions.[i] Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease and is associated with increased hospitalisations.[ii]

These data were presented at the International Society for Pharmacoeconomics and Outcomes Research Annual European Congress 2016, Austria.

IMPRESS is a retrospective observational study that demonstrates hospital resource use was significantly lower in the post-rifaximin-α initiation period, compared with the pre-rifaximin-α initiation period. Estimated cost reductions* per patient were;1

  • £2,031 in non-elective hospitalisations
  • £9,117 in critical care bed days
  • £121 in emergency room visits
  • £1,518 in 30-day emergency re-admissions

Peter Martin, Chief Operating Officer at Norgine said; “These data reinforce the value that XIFAXAN® 550mg / TARGAXAN® 550mg can bring to patients suffering from hepatic encephalopathy and to healthcare systems overall. By using XIFAXAN® 550mg / TARGAXAN® 550mg which reduces the recurrence of episodes of hepatic encephalopathy, hospitals can decrease the level of resources used. This in turn means lower costs for hospital admissions and bed occupancy.”

Hepatic encephalopathy affects around 10,000 patients in the UK.[iii]

XIFAXAN® 550mg / TARGAXAN® 550mg / TIXTELLER® 550mg is reimbursed through healthcare systems in Australia, England and Wales, Germany, Ireland, Italy, Luxembourg, New Zealand, Norway, Scotland, Sweden and Switzerland.

Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN® 550mg in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland.

Editor's Details

Mike Wood

Last updated on: 31/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.